-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Narsoplimab
| Category | SARS-CoV |
| CAS | 2108782-45-0 |
| Description | Narsoplimab is a human monoclonal antibody that targets mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. Narsoplimab has the potential for the treatment of high-risk transplant-associated thrombotic microangiopathy. |
Product Information
| Synonyms | OMS 721; Anti-MASP2 Reference Antibody (narsoplimab) |
| Purity | 95% |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
